Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02252597 1998-10-23
WO 97141164 PCT/GB97/01173
NON-THROMBOGENIC AND ANTI-THROMBOGENIC POLYMERS
SUMMARY OF INVENTION
This invention relates to the synthesis of polymers which
contain non-thrombogenic (NON-TH) as well as anti-thrombogenic
(ANTI-TH) properties. Such polymers can be conveniently
represented as follows:
POLYMER BACKBONE POLYMER BACKBONE
) and -____~_______~_____
(
[NON-TH] [NON-TH (
] [ANTI-TH]
Type 1 Type 2
In schematic diagrams of this kind, as used herein, the
designated side chains or groups can occur in any order and in
any relative proportions along the polymer backbone.
In polymers of Type 1 the non-thrombogenic (NON-TH) component
may consist of non-ionic hydrophilic domains, ionic domains,
zwitterionic domains or combinations of such domains. In novel
Type 1 polymers in accordance with the invention, such
non-thrombogenic components may be selected from, but are not
limited to, polymerisable sulphonates, polymerisable sulphates,
polymerisable N-sulphates (also known as sulphamates),
polymerisable zwitterionic compounds, and polymerisable
polyethylene glycols. When we synthesised polymers of Type 1,
without the anti-thrombogenic component, and coated various
medical devices, we found blood cell and protein deposition
reduced by greater than 90~. Greatly reduced (>95~) activation
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-2-
of white cells, platelets and complement was observed. This
type of synthetic polymer can be described as a
non-thrombogenic polymer.
The non-thrombogenic Type 1 polymer, as described, was
synthesised with polymerisable Heparin to give a Type 2
polymer. Surprisingly, the activity of the heparin was
retained in the Type 2 polymer and such polymers, when coated
on to medical devices, had the additional property of reducing
the thrombin-antithrombin complex concentration. This
inclusion of heparin into the non-thrombogenic polymer gave a
new polymer which additionally exhibited anti-thrombogenic
properties.
Another aspect of this invention is the process by which the
non-thrombogenic and anti-thrombogenic polymers are coated onto
medical devices.
BACKGROUND TO THE INVENTION
There is a growing interest in the use of artificial materials
in clinical practice where these materials are in continuous
contact with blood. Medical devices made from these materials
are required to perform in the harsh biological environment in
a specific application, for a specific duration without
stimulating a biological response which may prove to be
detrimental. Hence, such devices are required to be accepted
by the biological environment for a specific application and
duration, ie need to be bioacceptable. Improvements in
bioacceptability are highly desirable for medical devices
manufactured from artificial materials. Such materials
commonly include polyvinyl chloride, polyethylene,
polypropylene, polyurethanes, polycarbonates, stainless steel,
silicones and the like. The biological response to blood
contact with an artificial surface can be regarded in terms of
CA 02252597 1998-10-23
WO 97/41164 PCTIGB97/01173
-3-
different contributions from protein, platelet and blood cell
deposition, together with platelet and blood activation leading
to thrombus formation.
Many investigations have been carried out to prevent an
artificial surface from provoking thrombus formation, ie to
form a bioacceptable surf ace. Such investigations include the
use of polymers which are natural, hydrophilic, hydrophobic,
zwitterionic and charged (anionic and cationic). These types
of polymers are non-thrombogenic, have had limited success and
therefore application. Surface modification of an artificial
material by heparin (ie formation of an anti-thrombogenic
surface) has also proved to be intractable. Although clot
formation has been reduced, platelet activation and blood cell
activation are however still prevalent. Similarly, a
particular artificial surface may be resistant to protein,
platelet and blood cell deposition but may still activate blood
constituents.
Each surface, whether non-thrombogenic or anti-thrombogenic,
has its own profile of desirable bioacceptable properties, but
no particular material possesses the full spectrum of the
desired properties.
Additional disadvantages of some of the known approaches are
(i) the procedures used to produce these materials are complex,
(ii) the methods of applying these materials to the medical
device are elaborate, and (iii) these processes utilise
reagents which are highly toxic, even in minute quantities.
In a new approach to the problem of finding suitable
bioacceptable materials, we have synthesised a novel
non-thrombogenic polymer, and have also modified
non-thrombogenic polymers by incorporating a polymerisable
anti-thrombogenic compound, exemplified by polymerisable
heparin. It was found that heparin activity was maintained,
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-4-
while the non-thrombogenity of the polymer component was
prevalent. Other known biologically active anti-thrombogenic
compounds include hirudin, warfarin and hyaluronic acid, and
can be used in the same manner as the polymerisable heparin.
THE INVENTION
One embodiment of the present invention provides polymers
comprising a polymer backbone having pendant groups, obtainable
by polymerising monomers having such groups, characterized in
that said polymers are obtained by copolymerizing monomers of
at least three different classes selected from:
(a) monomers having sulphate groups
(b) monomers having sulphonate groups
(c) monomers having sulphamate groups, and
(d) monomers having polyoxyalkylene ether groups.
Another embodiment of the present invention provides polymers
comprising a polymer backbone having pendant groups, obtainable
by polymerising monomers having such groups, characterized in
that said polymers are obtained by copolymerizing monomers of
at least three different classes selected from:
(a) monomers having sulphate groups
(b) monomers having sulphonate groups
(c) monomers having sulphamate groups
(d) monomers having polyoxyalkylene ether groups, and
(e) monomers having zwitterionic groups.
A further embodiment of the present invention provides a method
of forming a coating of a polymer as described above on a
medical device by forming an ungelled partial polymer by
reacting a solution of an amine polymer with a crosslinking
agent, activating the medical device by solution coating with
said partial polymer, and depositing the polymer on the
resulting activated medical device.
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-5-
The present invention also provides a coating material
comprising a polymer as described above.
Without wishing to be bound by any theory or explanation of the
invention, it appears that non-thrombogenic surfaces have an
important impact on the first event of contact of blood with an
artificial surface. This event occurs almost instantaneously
and consists of protein adsorption. Subsequent events are
largely determined by interactions of blood with the adsorbed
protein. The nature of the artificial surface determines the
manner and extent of protein attachment.
For hydrophobic surfaces, attachment occurs by hydrophobic
interactions with the protein, which causes conformational
change of the adsorbed protein, exposing sites for protein
interaction resulting in further protein adsorption. The next
sequence of events has a pronounced influence in promoting
platelet adsorption/activation and white cell adsorption/
activation. The consequence of these events is the formation
of thrombus.
Protein adsorption on hydrophilic surfaces is more readily and
rapidly reversible than on hydrophobic surfaces. The extent of
reversibility is determined by the nature of the chemical bond
in the equilibrium state. At high states of reversibility,
protein adsorption is not prevalent and consequently platelet
and white cell adsorption/activation is prevented. Therefore,
thrombus formation is averted.
This type of hydrophilic surface is regarded as being
non-thrombogenic and in this respect we have found a new
a artificial hydrophilic polymer with at least three different
types of hydrophilic groups which include, but are not
restricted to, sulphonate, sulphate, N-sulphate (sulphamate) or
zwitterionic groups, and polyethylene glycol or glycol ether
units in the same polymer backbone.
CA 02252597 2004-08-03
-6-
In one embodiment of the present invention the non-thrombogenic polymer is
obtainable
by radical polymerisation, preferably of monomers having reactive carbon-
carbon double
bonds to form the polymer backbone and said monomer constituents containing,
but not
limited to, sulphonates, sulphates, N-sulphates (sulphamates), 2;witterions,
and
polyethylene glycol units, these monomer constituents being contained in the
same
polymer composition. Such monomers may be separated into three groups.
The first group is based on monomers derived from acrylates or methacrylates
of
sulphonates, sulphates and N-sulphates:
1) CHZ=CRl-C(=O)-Z1-RZ-Y~-X~
Where Rl is H or CH3;
RZ is a linear or branched alkylene of 2-10 carbon atoms, phenylene,
phenyl alkylene with 1-10 carbon atoms in the alkylene structure or the
polyoxyalkylene structure [CHZ-CHRI-O]"-CHZ-CHRI- where Rl is H
or CH3 and n is from 1 to 49;
Z, is oxygen (-O-) to give an ester linkage or secondary amine (-NH-)
to give an amide linkage;
Yl is (-O-) or (-NH-) or is absent; and
Xl is sulphonate (-S03-)
together with an acceptable balancing canon.
The second group is based on monomers derived from vinyl, aiiyl or methyl
allyl, of
sulphonates, sulphates and N-sulphates:
2) CHZ=CRS-RZ-Y~-X~
Where Rl is H or CH3;
RZ is a linear or branched alkylene of 1-10 carbon atoms, phenylene,
phenyl alkylene with 1-10 carbon atoms in the alkylene structure or
the polyoxyalkylene structure [CHZ-CHRI-O]n-CHZ-CHR1- where
Rl is H or CH3 and n is from 1 to 49;
CA 02252597 2004-08-03
_7_
Y1 is (-O-) or (-NH-) or is absent; and
Xl is sulphonate (-S03-)
together with an acceptable balancing canon.
In both groups of monomers (1) and (2),
when Y~ is (-O-), the monomer terminates in a sulphate group;
Y1 is (-NH-), the monomer terminates in a N-sulphate group;
RZ and Y, are not present, the monomer terminates in a sulphonate
group;
RZ is polyoxyalkylene and Yl is not present, the monomer
terminates in a sulphate group.
The third group of monomers is derived from acrylates or methacrylates of
polyoxyalkylene glycols or glycol ethers:
3) CHZ=CR3-C(=O)-O-[CHZ-CHR4-O]"-R~
Where R3 and R4, which may be the same or different, are each H or CH3,
R~ is H or alkyl with 1 to 5 carbon atoms, eg methyl, and
n is an integer from 2 to 50.
Monomer examples incorporating sulphonate groups include, but are not
restricted to, salts
of:
2-sulphoethyl methacrylate, 2-sulphoethyl acrylate, 3-sulphopropyl
methacrylate,
3-sulphopropyl acrylate, vinyl sulphonate, allyl sulphonate, methyl allyl
sulphonate,
p-styrene sulphonate, 2-acrylamido-methylpropanesulphonate, 3-sulphopropyl
ethoxy
methacrylate, 3-sulphopropyl ethoxy acrylate, 3-sulphopropyl polyoxyalkylene
methacrylate, 3-sulphopropyl polyoxyalkylene acrylate.
Similarly, examples of monomers terminating in sulphate groups include, and
are not
confined to, salts of:
CA 02252597 2004-08-03
_g_
2-sulphatoethyl methacrylate, 2-sulphatoethyl acrylate, 3-sulphatopropyl
methacrylate,
3-sulphatopropyl acrylate, 4-sulphatobutyl methacrylate, 4-sulphatobutyl
acrylate, allyl
sulphate, methyl allyl sulphate, 3-buten-1-sulphate, 3-buten-2-sulphate,
2-methyl-2-propene-1-sulphate, 2-methyl-3-buten-1-sulphate,
3-methyl-3-buten-1-sulphate, 2-sulphatoethyl methacrylamide, 2-sulphatoethyl
acrylamide, 3-sulphatopropyl methacrylamide, 3-sulphatopropyl acrylamide,
4-sulphatobutyl methacrylamide, 4-sulphatobutyl acrylamide, sulphato
polyoxyalkylene
methacrylate, sulphato polyoxyalkylene acrylate.
Examples of N-sulphate (sulphamate) containing monomers include, but are not
limited to,
salts o~
2-sulphamatoethyl methacrylate, 2-sulphamatoethyl acrylate, 3-sulphamatopropyl
methacrylate, 3-sulphamatopropyl acrylate, 4-sulphamatobutyl methacrylate,
4-sulphamatobutyl acrylate, allyl sulphamate, methyl allyl sulphamate, 2-
sulphamatoethyl
methacrylamide, 2-sulphamatoethyl acrylamide, 3-sulphamatopropyl
methacrylamide,
3-sulphamatopropyl acrylamide, 4-sulphamatobutyl methacrylamide, 4-
sulphamatobutyl
acrylamide, sulphamato polyoxyalkylene methacrylate, sulphamato
polyoxyalkylene
acrylate.
The salts used to form the polymers according to the invention, including
those listed
above, will have an acceptable, especially physiologically acceptable,
balancing canon
such as an alkali metal (eg sodium) canon, or an ammonium or substituted
ammonium
canon. Hydrogen cations usually provide a polymer that is too acidic for the
preferred
use.
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-9-
Other examples of non-thrombogenic polymers include those in
which zwitterionic monomers may be included in the above
formulations. For example, the non-thrombogenic polymers can
contain any zwitterionic monomer as an integral part of the
polymer backbone. The zwitterionic monomers may also be
included in the non-thrombogenic/antithrombogenic polymers.
Such zwitterionic monomers include, but are not limited to,
2-(methacryloyloxyethyl)-2'-(trimethylammonium) ethyl phosphate
inner salt and dimethyl (2-methacryloylethyl)-[1-(2-
sulphopropyl)] ammonium betaine inner salt.
A wide range of monomer compositions can be utilised in the
formation of the non-thrombogenic polymer. Such a polymer may
contain, and is not limited to, 3 to 4 different monomer
constituents. The ter-polymer (3 different monomers) and the
tetra-polymer (4 different monomers) are formulated from 3 or 4
respectively of at least one sulphate monomer type, at least
one sulphonate monomer type, at least one sulphamate monomer
type, and at least one polyoxyalkylene monomer type in the
final polymer composition. This polymer composition can
accordingly be schematically represented as follows, where the
relative frequency and the order of occurrence of each monomer
type are variable (being random co-polymers). In each instance
anions shown are balanced by acceptable cations, such as those
mentioned above.
a) ter-polymer i) POLYMER BACKBONE
) ) ~_____________
( ( (
S03- S04- [CH2-CHRl-O]n-CH3
ii) POLYMER BACKBONE
) ) ____________
( ( _ (
___NHS03___S~4___[CH2=CHR1=Ojn=CH3
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-10-
iii) POLYMER BACKBONE
__~_____________
( ( (
NHS03- S03- [CH2-CHR1-0]n-CH3
iv) POLYMER BACKBONE
~__________~_____
( ( (
NHS03- S04- S03
b) tetra-polymer POLYMER BACKBONE
__~______~_______-______
( ( (
(
NHS03- S03- S04- [CH2-CHR1-O]n-CH3
The above co-polymerised monomer compositions are examples of
non-thrombogenic (NON-TH) polymers represented above as Type 1.
In another aspect of this invention the non-thrombogenic
component is accompanied by a polymerisable anti-thrombogenic
component such as polymerisable heparin in the same polymer
backbone, and said anti-thrombogenic component in its bioactive
form being carried by an integral part of the aforementioned
polymer backbone.
Functionalisation of heparin by methacrylation of heparin is
known (ACS Symposium Series 77; Carbohydrate Sulphates, 1978).
Subsequent known polymerisations with other monomers give rise
to anti-thrombogenic polymers only, containing no
non-thrombogenic component (of the kind referred to herein).
This aspect of this invention accordingly provides a polymer
containing non-thrombogenic and anti-thrombogenic constituents
on the same polymer backbone. Preferred non-thrombogenic
constituents may comprise sulphate, sulphamate, sulphonate,
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-11-
zwitterionic and polyoxyalkylene glycol and glycol ether,
together with anti-thrombogenic constituents consisting of
polymerisable heparin bearing carbon-carbon double bonds.
Essentially the carbon-carbon double bond carried by the
heparin moiety is polymerisable by a free radical process and
may be by way of example vinyl, allyl, methyl allyl, acrylate
or methacrylate. Heparin linked to a component containing a
polymerisable carbon-carbon double bond is hereafter referred
to as heparin monomer. Corresponding monomers in which the
heparin is replaced by hirudin, warf arin or hyaluronic acid
moieties may be used in like manner.
The favoured heparin monomers are those in which heparin is
linked to a polyoxyalkylene methacrylate or polyoxyalkylene
acrylate through an ester or carbonate linkage. The ester or
carbonate linkage is formed by activating the hydroxyl
terminating polyoxyalkylene methacrylate or acrylate with
carbonyldiimidazole, forming the activated imidazoyl carbonate,
which subsequently is either coupled to carboxylic groups of
the heparin molecule to yield an ester linkage or coupled to
hydroxyl groups of the heparin molecule to yield a carbonate
linkage. This means of attaching the polyoxyalkylene
methacrylate or acrylate group to heparin allows polymerisation
of the heparin with the desired biological properties. Other
coupling techniques as described in WO 91/16932 using
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide result in
linkages occurring on sulphate groups of the heparin, called a
sulphonamide linkage. This coupling procedure results in poor
biological properties since these N-sulphate and sulphate
groups are important for binding to antithrombin.
Preferred heparin monomers include those of the following
formula
CA 02252597 1998-10-23
WO 97/41164 PCT/GB9'7/01173
-12-
(1) With ester linkage to heparin
CH2=CR5-C(=O)-O-CH2-CHR6-(O-CH2-CHR6-]n-p-C(=O)-Heparin
(2) With carbonate linkage to heparin
CH2=CRS-C(=O}-O-CH2-CHR6-[O-CH2-CHR6-]n-O-C(=0)-O-Heparin
In both general formulae, R5 and R6, which may be the same or
different, are each H or CH3; and n is an integer from 0 to 49.
Particularly preferred heparin monomers are those derived from
polyethylene oxide units, that is to say where R2 is H.
The heparin monomers (1) and (2), as above, are novel and are
other aspects of this invention and may be produced by reacting
hydroxyl terminated polyoxyalkylene with carbonyldiimidazole
[Im-C(=O)-Im] to form the activated imidazoyl carbonate:
CH2=CR5-C(=O)-O-CH2-CHR6-(0-CH2-CHR6-)n-0-C(=0)-Im
where R~, R6 and n have the meanings given above,
this being followed by the coupling of the activated imidazoyl
carbonate to heparin under basic pH conditions using
bicarbonate buffer at room temperature.
The heparin monomer is polymerised with the aforementioned
monomer of sulphate, sulphamate, sulphonate and
polyoxyalkylene, producing a polymer with both non-thrombogenic
and anti-thrombogenic properties. This polymer composition may
contain 4 to 5 of the different types of monomer constituent.
The tetra-polymer (4 different monomer types) and the
penta-polymer (5 different monomer types) are so formulated
from 3 or 4 respectively of at least one sulphate monomer type,
at least one sulphonate monomer type, at least one sulphamate
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-13-
monomer type, and at least one polyoxyalkylene monomer type,
together with at least one heparin monomer type, in the final
polymer composition. This polymer composition can accordingly
be schematically represented as follows, the relative frequency
and the order of occurrence of each monomer type being
variable. In each instance the anions shown are balanced by
acceptable cations, such as those mentioned above.
a) tetra-polymer i) POLYMER BACKBONE
~________________
( ( (
S03- S04" [CH2-CHR1-O]n-CH3 Hep
ii) POLYMER BACKBONE
___~_________________
( ( {
NHS03- S04- [CH2-CHR1-0]n-CH3~ Hep
iii) POLYMER BACKBONE
_____~________________
( (
NHS03- S03- [CH2-CHR1-0]n-CH3 Hep
iv) POLYMER BACKBONE
___~_________~____
( ( ( (
NHS03- S04- S03- Hep
b) penta-polymer POLYMER BACKBONE
) __~_____~_______________
( ( ( ( (
NHS03- S03- S04- [CH2-CHR1-0]n-CH3 Hep
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-14-
These non-thrombogenic/anti-thrombogenic (NON-TH/ANTI-TH)
polymers are of the kind represented above as Type 2.
Polymerisation may be carried out by conventional aqueous
solution polymerisation using a water soluble initiator, such
as potassium persulphate, after degassing the solution and
under an inert gas, such as nitrogen. Reaction temperature for
polymerisation is at room or elevated temperature, provided
that the heparin biological activity is not affected. The
preferred polymerisation temperature is one between 15 to 90°C,
and generally a polymerisation temperature of 75°C is suitable.
The polymer may be purified by conventional means, such as
precipitation, filtration wash and dialysis.
The aforementioned non-thrombogenic polymer or the
non-thrombogenic/anti-thrombogenic polymer according to the
invention is capable of being applied as a coating on medical
devices for use in blood-contacting applications. In this
regard, another aspect of this invention is the modification of
polyethylene imine or other primary or secondary amino
containing polymers to an extent that they form a stable
attachment between the medical device and the non-thrombogenic
polymer or the non-thrombogenic/ anti-thrombogenic polymer.
The use of unmodified polyethylene imine as an anchoring point
for heparin is known, EP 0124676. In these processes the
medical device requires chemical pre-treatment to allow
attachment of polyethylene imine to occur. Additionally,
multi-layers are built up on the device to ensure good coverage
and to enhance the stability of the attachment. These are
disadvantages which have severe impact on the performance and
the coating process. The heparin attached is grafted onto the
external polyethylene imine layer where surface covering is
limited. There is predominately preferential ionic bonding of
the heparin to the polyethylene imine. In such instances the
heparin may be released from the surface. This coating
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-15-
requires repeated steps to ensure that the polyethylene imine
is bound effectively. This has the constraint of increasing
the complexity of the process which results in high costs being
incurred.
To overcome the disadvantages mentioned above we have devised a
method for modifying primary or secondary amine polymers
including polyethylene imine which can be attached to the
medical device without any pre-treatment and can be carried out
in a single step. This is achieved by increasing the molecular
weight of the amine polymer, but to a limited extent, whereby
the polymer does not gel, but remains in solution. This can,
for instance, be achieved by crosslinking the amine, eg by
treatment with a crosslinking agent, such as an alkylene
diisocyanate, and/or with an alkyl isocyanate. The isocyanate
crosslinking agents mentioned above react very quickly with the
amino groups, but other crosslinking agents that are reactive
with amino groups may be employed. These include, but are not
limited to, diacids, diacid chlorides and cyclic anhydrides or
dianhydrides. Generally there will be 4 to 16 carbon atoms
between the active groups of the crosslinking agents. By
increasing the hydrophobic nature of the amine polymer in this
manner, it is capable of attaching to a suitable medical device
sufficiently to allow attachment of the non-thrombogenic
polymer or the non-thrombogenic/anti-thrombogenic polymer.
Hence the polymer coating process is essentially achieved in
two steps, as opposed to multiple steps.
Attachment of the polymer to the polyethylene imine pre-coating
can be enhanced by the incorporation of acrolein in the monomer
feed for the non-thrombogenic/anti-thrombogenic polymer, giving
aldehydic groups on the polymer backbone. These products are
also novel. The aldehydic groups are allowed to react with
amino groups on the modified polyethylene imine to form a
Schiff's base which is reduced to form a stable covalent bond.
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-16-
Alternatively the non-thrombogenic/anti-thrombogenic polymer
may be attached to the modified polyethylene imine by ionic
interaction.
The invention is illustrated by the following Examples, which
are not intended to restrict the scope of the invention. In
the Examples, concentrations are expressed as percentages
weight/volume, i.e. grams weight per 100m1 of solution.
The structure of the polymers whose preparation is identified
in the following Examples can be confirmed by the presence of
certain peaks in their FTIR spectra. These peaks include:
carbonate 1745.7 cm-1
methacrylate 870 cm-1 and 970 cm-1
carboxylic acid (sodium
salt or ester) 1609.8 cm-1
carbohydrate hydroxyl 3500 cm-1
C-O-C link in ester 1250 cm-1
rL~S t TO W THE O MATION OF NON muunMgOCFNIC POhYMFUS
ESP 1 P 1
Methoxy polyethyleneglycol methacrylate (MPEG METH., n=13,
9.0g), ammonium sulphatoethyl methacrylate (25~ aqueous
solution, 45g) and vinyl sulphonic acid sodium salt (25~
aqueous solution, 13g) were added to a 250m1 conical flask.
The contents of the flask were degassed for 30 minutes,
followed by bubbling with nitrogen and then heating to 75°C.
Potassium persulphate (100mg) was dissolved in water (15m1) and
added to the flask to start polymerisation. The reaction was
allowed to continue for 15 minutes after which a very viscous
solution was obtained. The reaction was stopped by pouring the
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-17-
contents of the flask into a beaker containing cold water
(100m1). The resultant polymer was dialysed against 10 litres
of water in cellulose acetate membrane, M.W. cut off at 12,000
to 14,000. The polymer was removed and concentrated to 150m1
and stored at 5°C. The anionic portion of the polymer
composition can be illustrated as follows:
POLYMER BACKBONE
) )_____________
( ( (
S03- S04- [CH2-CH2-O]13-CH3
Exam 1R a 2
Methoxy polyethyleneglycol methacrylate (MPEG METH., n=13,
7.7g), ammonium sulphatoethyl methacrylate (25~ aqueous
solution, 40.8g) and 2-sulphamatoethyl methacrylamide (25~
aqueous solution, 22.4g) were added to a 250m1 conical flask.
The contents of the flask were degassed for 30 minutes,
followed by bubbling with nitrogen aa~d then heating to 75°C.
Potassium persuiphate (100mg) was dissolved in water (15m1) and
added to the flask to start polymerisation. The reaction was
allowed to continue for 15 minutes after which a very viscous
solution was obtained. The reaction was stopped by pouring the
contents of the flask into a beaker containing cold water
(100m1). The resultant polymer was dialysed against 10 litres
of water in cellulose acetate membrane, M.W. cut off at 12,000
to 14,000. The polymer was removed and concentrated to 150m1
and stored at 5°C. The anionic portion of the polymer
composition can be illustrated as follows:
POLYMER BACKBONE
) ) _~____________
( ( (
NHS03- S04- [CH2-CH2-O]13-CH3
CA 02252597 1998-10-23
WO 97/41164 PCTlGB97/01173
-18-
Example 3
Methoxy polyethyleneglycol methacrylate (MPEG METH., n=13,
8.6g), 2-sulphamatoethyl methacrylamide (25~ aqueous solution,
45.2g) and vinyl sulphonic acid sodium salt (25g aqueous
solution, 14.4g) were added to a 250m1 conical flask. The
contents of the flask were degassed for 30 minutes, followed by
bubbling with nitrogen and then heating to 75°C. Potassium
persulphate (100mg) was dissolved in water (15m1) and added to
the flask to start polymerisation. The reaction was allowed to
continue for 15 minutes after which a very viscous solution was
obtained. The reaction was stopped by pouring the contents of
the flask into a beaker containing cold water (100m1). The
resultant polymer was dialysed against 10 litres of water in
cellulose acetate membrane, M.W. cut off at 12,000 to 14,000.
The polymer was removed and concentrated to 150m1 and stored at
5°C. The anionic portion of the polymer composition can be
illustrated as follows:
POLYMER BACKBONE
) ___~____________
{ ( {
NHS03- S03- [CH2-CH2-O]13-CH3
2-Sulphamatoethyl methacrylamide {25~ aqueous solution, 16.0g),
ammonium sulphatoethyl methacrylate (25~ aqueous solution,
59.6g) and vinyl sulphonic acid sodium salt (25~ aqueous
solution, 18.4g) were added to a 250m1 conical flask. The
contents of the flask were degassed for 30 minutes, followed by
bubbling with nitrogen and then heating to 75°C. Potassium
persulphate (100mg) was dissolved in water (15m1) and added to
the flask to start polymerisation. The reaction was allowed to
continue for 15 minutes after which a very viscous solution was
obtained. The reaction was stopped by pouring the contents of
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-19-
the flask into a beaker containing cold water (100m1). The
resultant polymer was dialysed against 10 litres of water in
cellulose acetate membrane, M.W. cut off at 12,000 to 14,000.
The polymer was removed and concentrated to 150m1 and stored at
5°C. The anionic portion of the polymer composition can be
illustrated as follows:
POLYMER BACKBONE
__
( (
NHS03" S04- S03
Methoxy polyethyleneglycol methacrylate (MPEG METH., n=13.
9.3g), 2-sulphamatoethyl methacrylamide (25~ aqueous solution,
17.6g), ammonium sulphatoethyl methacrylate (25~ aqueous
solution, 26.4g) and vinyl sulphonic acid sodium salt (25~
aqueous solution, 12.8g) were added to a 250m1 conical flask.
The contents of the flask were degassed for 30 minutes,
followed by bubbling with nitrogen and then heating to 75°C.
Potassium persulphate (100mg) was dissolved in water (15m1) and
added to the flask to start polymerisation. The reaction was
allowed to continue for 15 minutes after which a very viscous
solution was obtained. The reaction was stopped by pouring the
contents of the flask into a beaker containing cold water
(100m1). The resultant polymer was dialysed against 10 litres
of water in cellulose acetate membrane, M.W. cut off at 12,000
to 14,000. The polymer was removed and concentrated to 150m1
and stored at 5°C. The anionic portion of the polymer
composition can be illustrated as follows:
POLYMER BACKBONE
_~______~______________
( ( ( (
NHS03- S03- S04- [CH2-CHR1-O]13-CH3
CA 02252597 2004-08-03
-20-
EXAMPLE 6: THE FORMATION OF ACTIVATED IMIDAZOYL CARBONATE
Hydroxy polyethyleneglycol methacrylate (PEG, n=7, 1.0g) was added drop-wise
to
carbonyldiimidazole (Im-C(=O)-Im; O.Sg) in anhydrous dichloromethane to form
the
activated imidazoyl carbonate:
CHZ=C(CH3)-C(=O)-O-CHZ-CHZ-[O-CHz-CHZ-]~-O-C(=O)-Im
The solution was stirred for 3 hours for the reaction to be completed and
dichloromethane
was removed on a rotary evaporator.
EXAMPLE 7: FORMATION OF HEPARIN MONOMER
Heparin (injectable grade, S.Og) was dissolved in 30m1 of water. The heparin
solution was
then added to the activated imidazoyl carbonate formed in Example 6. The pH of
the
solution was adjusted to 8.5 to 9.0 by using potassium bicarbonate and and
solution was
stirred for 24 hours to form the heparin monomer. The solution was then
adjusted to pH7
with HCI.
EXAMPLES 8 TO 12: THE FORMATION OF NON-THROMBOGENIC/ANTI-
THROMBOGENIC POLYMERS
Example 8
Methoxy polyethyleneglycol methacrylate (MPEG METH., n=13, 9.0g), ammonium
sulphatoethyl methacrylate (25% aqueous solution, 45g), vinyl sulphonic acid
sodium salt
(25% aqueous solution, 13g) and the heparin monomer formed in Example 7 (5g)
were
added to a 250m1 conical flask. The contents of the flask were
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-21-
degassed for 30 minutes, followed by bubbling with nitrogen and
then heating to 75°C. Potassium persulphate (100mg) was
dissolved in water (15m1) and added to the flask to start
polymerisation. The reaction was allowed to continue for 15
minutes after which a very viscous solution was obtained. The
reaction was stopped by pouring the contents of the flask into
a beaker containing cold water (100m1). The resultant polymer
was dialysed against 10 litres of water in cellulose acetate
membrane, M.W. cut off at 12,000 to 14,000. The polymer was
removed and concentrated to 150m1 and stored at 5°C. The
anionic portion of the polymer composition can be illustrated
as follows:
POLYMER BACKBONE
) ) ) ________________~_
( ( ( (
S03- S04- [CH2-CH2-0]13-CH3 Hep
Methoxy polyethyleneglycol methacrylate (MPEG METH., n=13,
7.7g), ammonium sulphatoethyl methacrylate (25~ aqueous
solution, 40.8g), 2-sulphamatoethyl methacrylamide (25~
aqueous solution, 22.4g) and the heparin monomer formed in
Example 7 (5g) were added to a 250m1 conical flask. The
contents of the flask were degassed for 30 minutes, followed by
bubbling with nitrogen and then heating to 75°C. Potassium
persulphate (100mg) was dissolved in water (15m1) and added to
the flask to start polymerisation. The reaction was allowed to
continue for 15 minutes after which a very viscous solution was
obtained. The reaction was stopped by pouring the contents of
the flask into a beaker containing cold water (100m1). The
resultant polymer was dialysed against 10 litres of water in
cellulose acetate membrane, M.W. cut off at 12,000 to 14,000.
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-22-
The polymer was removed and concentrated to 150m1 and stored at
5°C. The anionic portion of the polymer composition can be
illustrated as follows:
POLYMER BACKBONE
) __~________________
( ( ( (
NHS03- S04- [CH2-CH2-O]13-CH3 Hep
Methoxy polyethyleneglycol methacrylate (MPEG METH., n=13.
8.6g), 2-sulphamatoethyl methacrylamide (25$ aqueous solution,
45.2g), vinyl sulphonic acid sodium salt (25~ aqueous solution,
14.4g) and the heparin monomer formed in Example 7 (5g) were
added to a 250m1 conical flask. The contents of the flask were
degassed for 30 minutes, followed by bubbling with nitrogen and
then heating to 75°C. Potassium persulphate {100mg) was
dissolved in water (15m1) and added to the flask to start
polymerisation. The reaction was allowed to continue for 15
minutes after which a very viscous solution was obtained. The
reaction was stopped by pouring the contents of the flask into
a beaker containing cold water (100m1). The resultant polymer
was dialysed against 10 litres of water in cellulose acetate
membrane, M.W. cut off at 12,000 to 14,000. The polymer was
removed and concentrated to 150m1 and stored at 5°C. The
anionic portion of the polymer composition can be illustrated
as follows:
POLYMER BACKBONE
) ) _~_________________
( { ( (
NHS03- S03- [CH2-CH2-O]13-CH3 Hep
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-23-
2-Sulphamatoethyl methacrylamide (25~ aqueous solution, 16.0g),
ammonium sulphatoethyl methacrylate (25g aqueous solution,
59.6g), vinyl sulphonic acid sodium salt (25~ aqueous solution,
18.4g) and the heparin monomer formed in Example 7 (5g) were
added to a 250m1 conical flask. The contents of the flask were
degassed for 30 minutes, followed by bubbling with nitrogen and
then heating to 75°C. Potassium persulphate (100mg) was
dissolved in water (15m1) and added to the flask to start
polymerisation. The reaction was allowed to continue for 15
minutes after which a very viscous solution was obtained. The
reaction was stopped by pouring the contents of the flask into
a beaker containing cold water (100m1). The resultant polymer
was dialysed against 10 litres of water in cellulose acetate
membrane, M.W. cut off at 12,000 to 14,000. The polymer was
removed and concentrated to 150m1 and stored at 5°C. The
anionic portion of the polymer composition can be illustrated
as follows:
POLYMER BACKBONE
)
( ( ( (
NHS03- S04- S03 Hep
Methoxy polyethyleneglycol methacrylate (MPEG METH., n=13,
9.3g), 2-sulphamatoethyl methacrylamide (25~ aqueous solution,
17.6g), ammonium sulphatoethyl methacrylate (25~ aqueous
solution, 26.4g), vinyl sulphonic acid sodium salt (25~ aqueous
solution, 12.8g) and the heparin monomer formed in Example 7
(5g) were added to a 250m1 conical flask. The contents of the
flask were degassed for 30 minutes, followed by bubbling with
nitrogen and then heating to 75°C. Potassium persulphate
(100mg) was dissolved in water (15m1) and added to the flask to
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-24-
start polymerisation. The reaction was allowed to continue for
15 minutes after which a very viscous solution was obtained.
The reaction was stopped by pouring the contents of the flask
into a beaker containing cold water (100m1). The resultant
polymer was dialysed against 10 litres of water in cellulose
acetate membrane, M.W. cut off at 12,000 to 14,000. The
polymer was removed and concentrated to 150m1 and stored at
5°C. The anionic portion of the polymer composition can be
illustrated as follows:
POLYMER BACKBONE
) ~______~_________________
( ( ( ( (
NHS03- S03- S04- [CH2-CHR1-0]13-CH3 Hep
~,x~mNr_.~~ 13 AND 14- MODIFrCAmTON OF POLVFTUVrFrT~ TMT,, (pEI)
PEI was supplied as a 50~ solution in water by BASF,
approximate molecular weight is 20,000.
PEI (140g) was dissolved in 1 litre of isopropanol.
Hexamethylene diisocyanate (2.8g) was dissolved in 50m1 of
acetone. The diisocyanate solution was added drop-wise to the
PEI solution. The final solution was then rotary evaporated to
remove the isopropanol (500m1).
Example 14
PEI (140g) was dissolved in 500m1 of isopropanol.
Hexamethylene diisocyanate (1.4g) was dissolved in 50m1 of
CA 02252597 1998-10-23
WO 97/41164 PCT/GB97/01173
-25-
acetone. The diisocyanate solution was added drop-wise to the
PEI solution. A solution of n-butyl isocyanate (2.0g in 50m1
acetone) was then added drop-wise to the solution.
Five mole percent of acrolein is added to the monomer feed in
the formation of the non-thrombogenic polymer or the
non-thrombogenic/anti-thrombogenic polymer. This allows
chemical linkage to the modified polyethylene imine.
The modified polyethylene imine as prepared in Example 13 is
diluted to give a final composition of 0.23. The pH of the
solution is in the region of 9.5 to 10. Samples of medical
devices, generally tubing, connectors and the like are coated
by incubating in the solution for 10 minutes, and then washed
with distilled water. Typically, the tubing may by polyvinyl
chloride, polyethylene or silicone, and the connectors
polycarbonate or polyvinyl chloride.
The non-thrombogenic polymer or the non-thrombogenic/
anti-thrombogenic polymer is prepared as in the aforementioned
Examples and is diluted with water to give a final polymer
concentration of 0.08 (w/v). The pH of the solution is
adjusted to 8.5 with sodium tetraborate. After the samples
have been incubated in the modified polyethylene imine, as
described in Example 15, the samples are incubated in the
CA 02252597 1998-10-23
WO 97141164 PCT/GB97/01173
-26-
non-thrombogenic polymer or the non-thrombogenic/
anti-thrombogenic polymer for 10 minutes. The samples are then
washed and tested for haemocompatibility.
The polymer from Example 1 (non-thrombogenic polymer) and
Example 8 (non-thrombogenic/anti-thrombogenic polymer) were
assessed for haemocompatibility. The results showed that in
both types of polymers, Example 1 (non-thrombogenic polymer)
and Example 8 (non-thrombogenic/anti-thrombogenic polymer),
when coated on medical devices, the blood cell and protein
deposition was reduced by greater than 90~ and also greatly
reduced (>95~) activation of white cells, platelets and
complement activation. Medical devices coated with the product
of Example 8 (non-thrombogenic/anti-thrombogenic polymer)
showed the additional property of reducing the
thrombin-antithrombin complex concentration.
